TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cerebral tissue oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Concentration-time Curve of BI 1323495 in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of severe dengue disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower levels of sex-related HIV risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bioequivalency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With the Indicated CNS Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With the Indicated CNS Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: symptom-medication score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Side effect profile of drug combination
Endpoint domain: Adverse events/effects
Primary endpoint: Assess plasma pharmacokinetics of fenretinide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MADRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of autoantibodies against ghrelin and alpha-MSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Left ventricular ejection fraction recuperation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Pathologic complete response (tpCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Subjects With Device-and/or Injection-related Severe Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Fractional synthesis of collagen in keloid scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinician's Parkinson's Disease Knowledge Assessment Survey Scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in transferrin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIV Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of RAO after transradial approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Free circulating DNA as a toxicity biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate level in blood from fetal scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lactate level in blood from umbilical artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lactate level in blood from umbilical vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: blood volume deviation (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Complete Ulcer Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pathological tau deposition in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Scoliosis Curve Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle of Trunk Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in psychomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse changes in mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent Change in Oxygen Saturation (SpO2) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Mean Heart Rate From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mean Pulmonary Artery Pressure (mPAP) From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with Lysholm score more than 70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical assessment of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Chats on Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Number of Chats on Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Chats on Infant Nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Surgical Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Tumour immune gene expression signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathology regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune T-cell infiltration before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Hepatic Glycogen Concentration Adjusted for Liver Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change in Fasting Hepatic Glycogen Concentration Adjusted for Liver Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of Children with Persistent Post-concussive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Experiencing Re-bleed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Reproductive hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in NRS knee pain intensity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Volume Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of bortezomib in combination with CC-5013
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose of BKM120
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HPV type distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to accrual of 500 participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Retention at 24 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Abstained From Smoking Cigarettes at 6 months (Prolonged Abstinence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Abstained From Smoking Cigarettes at 12 Months (Prolonged Abstinence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Abstained From Smoking Part of a Cigarette at 6 months (30-day Point Prevalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Abstained From Smoking Part of a Cigarette at 12 Months (30-day Point Prevalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct Drug Identity by Shape
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct Drug Identity by Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct Dose Frequency by Tactile Protrusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of myostatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in postoperative intravenous opioid dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma symptoms changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of amino acids, glucose, and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose of dexmedetomidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with specified AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Time to onset of first specified AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Summary of duration of specified AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events/adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Match of EyeArt results with reading center grading for diabetic eye disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of suicide ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative closure time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: hemodynamic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in taxane induced peripheral neuropathy symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pancreatic insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Blood flow to pancreas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Treatment Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Radiologic Response Rate Of Cryoablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Total Score of Depression, Anxiety, and Stress Scales-42 (DASS-42)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment response prediction using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HgbA1c measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prostate-specific antigen (PSA) decline >=50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with central T2/FLAIR hyposignal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient's Pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Uptake of Glucose and Ketone Bodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Rating Scale For Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burn-out Assessment tool (BAT) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reward-related activity in response to food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of local and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Lung Areation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve for 0 to 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Progesterone Levels Above 3.0 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clearance (L/hr) of Levonorgestrel Over 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subendometrial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ferric Reducing Antioxidant Potential (FRAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Thiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction in Quality of Life (LUP-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Satisfaction in Quality of Life (FACIT-F)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Days Free From Diaper Dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Disabling Stroke Rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Retained at the End of Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Self-monitored Step Count Using Wrist Worn ActiGraph GT9X Over the Study Period
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of PATH Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in ESSDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palliative Care Outcome Scale - Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Care Assessment Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Oswestry Disability Index 2.0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of relapses by 24 months following treatment cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MDS TBR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast tissue gene pathway gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Overall Neuropathy Limitation Scale (ONLS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of surgical management types
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants With Grade ≥3 Adverse Events Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: reduction in pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of gait kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline UDP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline NDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline GONIOMETER
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a HbA1c less than 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants free of severe hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Early renal function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Event (TEAE) of Pneumonitis by Grade
Endpoint domain: Adverse events/effects
Primary endpoint: major hematologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: MFVDA-SRS responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue rate
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Muscle response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of the modified Rodnan skin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in CK levels at 6 months compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COMFORT score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: neural changes after multi-session tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: network changes after multi-session tDCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity and specificity of the HelioLiver Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Easy of Communication Scale
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Change in the Intelligibility Subscale of the Frenchay Dysarthria Assessment Tool
Endpoint domain: Life impact
Endpoint subdomain: Communication
Primary endpoint: Frequency of atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of other postoperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Pain/Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Patients With GPPGA Pustulation Subscore of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Serum Concentration (Cmin) of TCZ at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax) of TCZ at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthetic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum percentage of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Cocaine Positive Urine Toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of TNX-102 SL 5.6 mg versus TNX-102 SL 2.8 mg under fasting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) of TNX-102 SL 2.8 mg versus TNX-102 SL 5.6 mg under fasting conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of port-site hernia
Endpoint domain: Adverse events/effects
Primary endpoint: Grip and Pinch Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of autoimmune disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence Rate of SCAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruton's Tyrosine Kinase (BTK) Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Upper Extremity Skills Test (QUEST) Score - Section on Dissociated Movements
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Quality of Upper Extremity Skills Test (QUEST) Score - Section on Grasp
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall Survival (OS) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Life Measurements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: % relative change in steady hyperemia FFR (sFFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Upper respiratory infection incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Dental pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in physiological parameters (arterial oxygen saturation and pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practitioner's assessment of patient pain-related comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of post-op complication
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics (AUC(0-t), AUC(0-8), Cmax, tmax, AUC(0-24), t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in VVA symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes